Skip to main content

Table 5 Relationship between the incidence of the primary endpoint and the TyG index expressed as a categorical variable

From: Triglyceride glucose index for predicting cardiovascular outcomes after percutaneous coronary intervention in patients with type 2 diabetes mellitus and acute coronary syndrome

VariablesUnivariate analysis
HR (95% CI)
P valueMultivariate analysis
HR (95% CI)
P-value
TyG index tertiles
 T1Reference Reference 
 T21.74 (1.17–2.57)0.0061.60 (1.06–2.40)0.025
 T32.27 (1.56–3.32)< 0.0012.15 (1.44–3.22)< 0.001
 Age1.01 (0.99–1.02)0.4580.99 (0.97–1.004)0.138
 BMI0.98 (0.94–1.02)0.3000.97 (0.92–1.01)0.166
 DBP0.98 (0.96–0.99)0.0010.99 (0.97–1.00)0.048
 HDL-C0.98 (0.96–1.00)0.0140.98 (0.96–1.00)0.042
 Glycosylated haemoglobin1.05 (0.94–1.18)0.3870.93 (0.82–1.06)0.307
 Male sex0.92 (0.67–1.26)0.6030.68 (0.44–1.04)0.077
 Current smoking0.94 (0.70–1.27)0.6991.02 (0.71–1.46)0.918
 Daily drinking1.01 (0.62–1.65)0.9571.30 (0.77–2.18)0.330
 Previous MI1.52 (1.11–2.09)0.0090.88 (0.61–1.27)0.500
 Past PCI1.79 (1.33–2.41)< 0.0011.72 (1.17–2.53)0.006
 PAD2.82 (2.05–3.87)< 0.0012.22 (1.52–3.24)< 0.001
 CKD1.70 (1.07–2.70)0.0251.46 (0.85–2.52)0.172
 Cardiac failure2.27 (1.52–3.40)< 0.0011.59 (1.00–2.52)0.049
 Insulin at discharge1.39 (1.04–1.87)0.0250.95 (0.67–1.36)0.797
 Metformin at discharge1.12 (0.76–1.63)0.5681.08 (0.72–1.62)0.707
 Alpha-glucosidase inhibitors at discharge0.89 (0.66–1.21)0.4570.76 (0.55–1.06)0.104
 Sulfonylurea at discharge0.89 (0.64–1.26)0.5240.95 (0.65–1.38)0.784
 Dipeptidyl peptidase 4 inhibitors at discharge1.34 (0.50–3.60)0.5661.24 (0.44–3.48)0.685
CAD severity
 One-vessel diseaseReference Reference 
 Two-vessel disease2.08 (0.87–5.01)0.1011.30 (0.52–3.24)0.579
 LM/three-vessel disease4.32 (1.91–9.76)< 0.0012.16 (0.91–5.13)0.079
 Lesions > 20 mm long2.07 (1.51–2.84)< 0.0011.59 (1.13–2.23)0.008
 DCB use2.07 (1.33–3.23)0.0011.23 (0.73–2.08)0.430
 Complete revascularization0.46 (0.35–0.62)< 0.0010.63 (0.46–0.86)0.004
  1. Abbreviations as in Tables 1 and 2